In this second edition of his popular and widely acclaimed book, Eric Klein, MD, and a panel of leading authorities have thoroughly updated and revised its contents to include all the latest observations and developments that will shape the direction of clinical practice and research over the next 5-10 years. Here, the reader will find in concise form accounts of the latest trends in diagnosis and mortality, new PSA isoforms for diagnosis, PSA screening, chemoprevention, biopsy techniques, sural nerve grafting, and hereditary prostate cancer. Additional chapters reflect progress in the management of locally advanced disease, the use of nomograms to predict outcomes, the medical management of erectile dysfunction, brachytherapy, and deciding between surgery and radiation. The chapters on open and laparoscopic techniques, the selection of candidates for observation, pathological analysis, quality of life, and the management of rising PSA after definitive therapy have been extensively updated. A compact disk accompanies the book for downloading an ebook to the reader's PC or PDA.
Up-to-date and eminently practice-oriented, Management of Prostate Cancer, Second Edition, offers every physician-especially front-line urologists, radiation therapists, and medical oncologists-concise and authoritative guidance on today's best therapeutic regimens for the diagnosis and treatment of prostate cancer.

Klappentext

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5-10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual's chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Inhalt

Part I. Screening, Risk Factors, Diagnosis, and Prevention Prostate Cancer Overdiagnosis and Overtreatment: Analysis of US Mortality and SEER Incidence Trends in the PSA and Pre-PSA Eras Robert A. Stephenson Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2: Clinical Application for Early Detection and Staging of Prostate Cancer Alexander Haese and Alan W. Partin Defining an Optimum PSA-Based Screening Strategy for Young Men Judd W. Moul Hereditary Prostate Cancer and Genetic Risk Phillippa J. Neville, Graham Casey, and John S. Witte Strategies for the Chemoprevention of Prostate Cancer Ronald Lieberman, Jacob Kagan, Margaret G. House, Joseph Kelaghan, David J. Kausal, and Howard L. Parnes The Special Problems of Prostate Cancer Among African Americans: Clinical and Molecular Factors Isaac J. Powell Current Issues in Pathologic Evaluation Howard S. Levin Current Trends in Biopsy Techniques Joseph C. Presti, Jr. Part II. Localized Disease: Treatment and Outcomes Predicting Outcomes: Artificial Neural Networks and Nomograms Audrey C. Rhee, Christopher J. Di Blasio, Daniel Cho, and Michael W. Kattan When Is Observation Appropriate? Kisseng Hsieh and Peter C. Albertsen Contemporary Technique of Radical Prostatectomy: Open Approach Eric A. Klein Contemporary Technique of Radical Prostatectomy: Laparoscopic Approach Sidney C. Abreu, Andrew P. Steinberg, and Inderbir S. Gill Contemporary Technique of Radical Prostatectomy: Perineal Approach Vernon E. Weldon Anesthetic Considerations for Contemporary Radical Prostatectomy Jerome F. O'Hara, Jr. and David Whalley Conformal External Beam Radiotherapy Arul Mahadevan and Patrick A. Kupelian Brachytherapy Kenneth W. Angermeier and Jay P. Ciezki Androgen Deprivation and Radiation Therapy for Localized Prostate Cancer Patrick A. Kupelian and Tom Carlson Prostate Brachytherapy: The Role of Supplemental External Beam Radiotherapy Gregory S. Merrick and Wayne M. Butler Health-Related Quality of Life Issues John T. Wei and David Miller The Evaluation and Management of Postprostatectomy Urinary Incontinence Adonis Hijaz, M. Louis Moy, Sandip P. Vasavada, and Raymond R. Rackley Sural Nerve Grafting During Radical Prostatectomy: Techniques and Results Edward D. Kim Management of Erectile Dysfunction Following Radical Prostatectomy Craig D. Zippe and Rupesh Raina Counseling Patients With Localized Prostate Cancer: Radiation or Surgery? Eric A. Klein and Patrick A. Kupelian Counseling the Patient With Prostate Cancer: The Radiation Oncologist's Perspective Anthony Zietman Counseling Patients on Choice of Therapy: The Medical Oncologist's Perspective Celestia S. Higano Emotional and Informational Support for the Patient Undergoing Radical Prostatectomy Dorothy A. Calabrese Prostate Cancer: A Survivor's View Nathaniel K. Cooke Prostate Cancer: A Spouse's View Nancy L. Cooke Part III. Advanced Disease Management of PSA Recurrence After Definitive Therapy for Prostate Cancer Ilia S. Zeltser, Richard K. Valicenti, and Leonard G. Gomella When to Refer a Patient With Prostate Cancer to a Medical Oncologist: The Earlier the Better Jeanne Smoot and Nancy A. Dawson Management of Newly Diagnosed Metastatic Disease Thomas E. Hutson Management of the Patient With Androgen-Independent Metastatic Prostate Cancer Robert Dreicer Bone-Targeted Therapy for Prostate Cancer Navjeet Gandhok and Oliver Sartor Part IV. Applied Molecular Biology